NV-VELODYNE-LIDAR,-INC.
4.1.2019 20:02:08 CET | Business Wire | Press release
In advance of CES, Velodyne Lidar, Inc. today introduced trailblazing technology that will serve as the cornerstone of future advanced driving safety systems. The new products strengthen Velodyne’s position as the industry leader in providing the smartest, most powerful lidar solutions for vehicle autonomy and driver assistance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190104005457/en/
Velodyne unveiled the VelaDome™, a compact embeddable lidar that provides an ultra-wide 180° x 180° image for near-object avoidance. Velodyne also introduced Vella™, breakthrough software that establishes its directional view Velarray™ lidar sensor as an integral component for advanced driver assistance systems (ADAS).
“With these new products, Velodyne’s robust solution portfolio meets the entire range of lidar needs for autonomy and driver assistance,” said Anand Gopalan, Ph.D., Chief Technology Officer (CTO) at Velodyne Lidar. “David Hall first deployed vehicle software in 2004 as part of the DARPA Challenges. Over the last 15 years, Velodyne has continued to add intelligence to our sensors, enabling a variety of lidar sensing capabilities that allow our customers to detect more objects and offer cars a more detailed view of their surroundings. Now we will take it even further and our new software, which was developed in close collaboration with our lidar hardware experts, will enable a seamlessly integrated ADAS solution powered by our lidars.”
The Lidar Assistant (Vella): Software that Revolutionizes ADAS Performance
Velodyne presented a groundbreaking advanced driver assistance solution that builds upon its directional view Velarray sensor. Vastly superior to existing approaches that utilize camera+radar, this solution will revolutionize advanced driver assistance functionalities currently on the market, such as Lane Keeping Assist (LKA), Automatic Emergency Braking (AEB), and Adaptive Cruise Control (ACC).
VelaDome: Close-Range Precision
The VelaDome’s game-changing hemispherical field of view and high-density image present a quantum leap in pedestrian, cyclist, and blind-spot detection. The compact sensor is ideal for a variety of mounting and styling options. Powered by Velodyne’s patented Micro Lidar Array (MLA) technology, the VelaDome is optimized for manufacturability and designed to meet automotive-grade standards. Like all Velodyne sensors, VelaDome has world-class technical support available across North America, Europe, and Asia.
For more information on Velodyne and to download news releases, photos, and videos, please visit https://velodynelidar.com/newsroom/ . Media can schedule an executive interview or product demo by contacting Robin Carr at Landis Communications Inc. (415-971-3991; velodyne@landispr.com ).
About Velodyne Lidar
Velodyne provides the smartest, most powerful lidar solutions for autonomy and driver assistance. Founded in 1983 and headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. In 2005, Velodyne’s Founder and CEO, David Hall, invented real-time surround view lidar systems, revolutionizing perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the perfect for L4-L5 autonomy Alpha Puck™, the ultra-wide angle VelaDome™, and the ADAS-optimized Velarray™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190104005457/en/
Contact:
Robin Carr Landis Communications Inc. (415) 971-3991 velodyne@landispr.com www.landispr.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom